Lantern Pharma Inc (LTRN)

Jan 28, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World

Jan 28, 2025

Jan 27, 2025

Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance

Jan 27, 2025

Jan 27, 2025

Top 10 AI Stocks Dominating Wall Street - Insider Monkey

Jan 27, 2025

Jan 27, 2025

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace

Jan 27, 2025

Jan 27, 2025

Lantern Pharma's AI Platform Breakthrough: 82 New ADC Targets Could Slash Development Time 50% - StockTitan

Jan 27, 2025

Jan 21, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jan 21, 2025

Jan 17, 2025

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey

Jan 17, 2025

Jan 10, 2025

Lantern Pharma Extends CSO’s Employment Agreement - TipRanks

Jan 10, 2025

Jan 04, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World

Jan 04, 2025

Jan 02, 2025

Oncology Drugs Fast-Tracked by the FDA in December 2024 - Oncology News Central

Jan 02, 2025

Dec 22, 2024

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance

Dec 22, 2024

Dec 10, 2024

AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey

Dec 10, 2024

Dec 09, 2024

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance

Dec 09, 2024

Dec 09, 2024

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire

Dec 09, 2024

Dec 07, 2024

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance

Dec 07, 2024

Dec 06, 2024

15 AI News Updates That Broke The Internet - Insider Monkey

Dec 06, 2024

Dec 03, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Dec 03, 2024

Dec 03, 2024

Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com

Dec 03, 2024

Dec 03, 2024

LP-184 gains FDA fast track for triple negative breast cancer - Investing.com

Dec 03, 2024

Dec 03, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune

Dec 03, 2024

Nov 26, 2024

Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - BioSpace

Nov 26, 2024

Nov 21, 2024

10 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Nov 21, 2024

Nov 20, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 19, 2024

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace

Nov 19, 2024

Nov 19, 2024

Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com

Nov 19, 2024

Nov 19, 2024

Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan

Nov 19, 2024

Nov 14, 2024

32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.

Nov 14, 2024

Nov 13, 2024

III: TechBio News Day 👾 - substack.com

Nov 13, 2024

Nov 12, 2024

LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India

Nov 11, 2024

Nov 09, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada

Nov 09, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks

Nov 08, 2024

Nov 07, 2024

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace

Nov 07, 2024

Nov 05, 2024

Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Yahoo Finance

Nov 05, 2024

Oct 31, 2024

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine

Oct 31, 2024

Oct 31, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace

Oct 31, 2024

Oct 29, 2024

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com

Oct 29, 2024

Oct 23, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire

Oct 23, 2024

Oct 21, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire

Oct 21, 2024

Oct 17, 2024

LP-184 Earns FDA Fast Track Designation in Glioblastoma - Targeted Oncology

Oct 17, 2024

Oct 16, 2024

FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada

Oct 16, 2024

Oct 15, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace

Oct 15, 2024

Oct 15, 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive

Oct 15, 2024